Drug Topics column takes up FDA's evaluation of peptides
The Pharmacy Law Lowdown segment addresses how the agency is assessing peptide substances, a live question for compounders.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 14:06 ETSource: Drug Topics
The wire
- 01Drug Topics' Pharmacy Law Lowdown segment covers FDA's evaluation of peptides.
- 02Compounding pharmacists and prescribers track FDA's peptide categorization closely because it determines which substances can lawfully be compounded.
- 03Details of the agency's current position were not set out in the item; readers should check FDA's own category listings for the operative status of individual peptides.
From the source
Read at drugtopics.comPharmacy Law Lowdown: FDA’s Evaluation of Peptides
